<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845323</url>
  </required_header>
  <id_info>
    <org_study_id>J1682</org_study_id>
    <secondary_id>IRB00103062</secondary_id>
    <nct_id>NCT02845323</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder</brief_title>
  <official_title>Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the post cystectomy CD8+ tumor response of patients receiving Nivolumab&#xD;
      plus Urelumab versus Nivolumab alone. Half the patients will receive Nivolumab plus Urelumab,&#xD;
      while the other half will receive Nivolumab alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is phase II clinical trial design randomizing patients who are cisplatin-ineligible or&#xD;
      chemotherapy-refusing with MIBC (stages T2-T4, N0-N2, M0) to one of two treatment arms: Arm A&#xD;
      - Nivolumab in combination with Urelumab or Arm B - Nivolumab monotherapy.&#xD;
&#xD;
      The study population will include male and female patients over the age of 18 with muscle&#xD;
      invasive urothelial carcinoma of the bladder (MIBC) who are not suitable for cisplatin-based&#xD;
      chemotherapy or refuse chemotherapy, but are fit to undergo surgical resection of their&#xD;
      cancer by cystectomy. Patients with resectable clinical node positive disease within the true&#xD;
      pelvis are eligible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response to treatment with Nivolumab and Urelumab compared to Nivolumab monotherapy measured by tumor infiltrating CD8+ T cell density at cystectomy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number of participants with treatment-related adverse events as assessed by CTCAE v 4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving pathologic response (&lt;pT2N0) with Nivolumab and Urelumab and the use of Urelumab alone</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of tumor biopsy PD-1 and PD-L1 expression and change in expression for pathologic tumor response as defined by cystectomy pathologic staging &lt;pT2 N0 in patients treated with Nivolumab</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression for pathologic tumor response as defined by cystectomy pathologic staging &lt;pT2 N0 in patients treated with Nivolumab</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of tumor bx 4-1BB (CD137)&amp; 4-1BB ligand (CD137L) expression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression, assessed by (IHC) analysis, for tumor response, defined by cystectomy staging &lt; pT2N0, in cisplatin-ineligible MIBC pts tx w/Urelumab.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of tumor biopsy 4-1BB expression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression, assessed by (IHC) analysis, for pathologic CR response, defined by cystectomy staging pT0N0, in cisplatin-ineligible MIBC pts tx w/ Urelumab.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving pathologic complete response with neoadjuvant Nivolumab and Urelumab (Arm A) and Nivolumab monotherapy (Arm B).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab in combination with Urelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and Urelumab combination:&#xD;
Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles&#xD;
Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab in combination with Urelumab</intervention_name>
    <description>Two cycles of Nivolumab Two cycles of Urelumab</description>
    <arm_group_label>Nivolumab in combination with Urelumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab monotherapy</intervention_name>
    <description>Two cycles of Nivolumab alone</description>
    <arm_group_label>Nivolumab monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Electively refusing cisplatin-based neoadjuvant chemotherapy or&#xD;
&#xD;
          -  Ineligible to receive cisplatin-based neoadjuvant chemotherapy based upon at least one&#xD;
             of the following criteria:&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  ECOG status =2&#xD;
&#xD;
          -  Grade &gt; 2 hearing loss&#xD;
&#xD;
          -  Grade &gt; 2 neuropathy&#xD;
&#xD;
          -  New York Heart Association Class III heart failure&#xD;
&#xD;
          -  Age ≥ 18 years old at time of consent&#xD;
&#xD;
          -  Patients must have the following laboratory values:&#xD;
&#xD;
             a) Absolute neutrophil count (ANC) ≥ 1.5 K/mm3 (must be stable off any growth factor&#xD;
             within 4 weeks of first study drug administration) b) Platelets ≥ 100 K/mm3&#xD;
             (transfusion to achieve this level is not permitted within 2 weeks of first study drug&#xD;
             administration) c) Hemoglobin (Hgb) ≥ 9 g/dL d) Serum total bilirubin: ≤ 1.5 x ULN e)&#xD;
             ALT and AST ≤ 3.0 x ULN f) Serum creatinine clearance (CrCl) ≥ 30 mL/min using the&#xD;
             Cockcroft-Gault equation, see formula below:&#xD;
&#xD;
          -  CrCl = [140-age (years)] x weight (kg) / [72 x serum Cr (mg/dL)] (if patient is female&#xD;
             multiply the above by 0.85)&#xD;
&#xD;
          -  Patients who give a written informed consent obtained according to local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with locally advanced unresectable or metastatic urothelial carcinoma as&#xD;
             assessed on baseline radiographic imaging obtained within 28 days prior to study&#xD;
             registration. The required radiographic imaging includes:&#xD;
&#xD;
             a) Abdomen/Pelvis - CT scan b) Chest - chest x-ray or CT scan&#xD;
&#xD;
          -  Patients with concurrent upper urinary tract (i.e. ureter, renal pelvis) invasive&#xD;
             urothelial carcinoma.&#xD;
&#xD;
          -  Patients with another active second malignancy other than non-melanoma skin cancers&#xD;
             and biochemical relapsed prostate cancer&#xD;
&#xD;
          -  Patients who have received the last administration of an anti-cancer therapy including&#xD;
             chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting&#xD;
             study drug, or who have not recovered from the side effects of such therapy&#xD;
&#xD;
          -  Patients who have received prior therapy with immune checkpoint inhibitors (e.g.&#xD;
             anti-PD-1, anti-PD-L1, anti-LAG3, anti-CTLA-4) or immune costimulatory molecules (e.g.&#xD;
             anti-CD137, anti-OX40, anti-GITR) directed agents.&#xD;
&#xD;
          -  Patients who have had radiotherapy ≤ 4 weeks prior to starting study drug, or who have&#xD;
             not recovered from radiotherapy toxicities&#xD;
&#xD;
          -  Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or&#xD;
             intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting&#xD;
             study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous&#xD;
             biopsies or placement of vascular access device ≤ 1 week prior to starting study drug,&#xD;
             or who have not recovered from side effects of such procedure or injury&#xD;
&#xD;
          -  Patients with history of alcoholic or non-alcoholic steatohepatitis (NASH),&#xD;
             auto-immune hepatitis, or previous grade 3-4 drug-related hepatitis. (Note: Patients&#xD;
             with radiographic evidence of steatohepatitis are excluded unless a liver biopsy is&#xD;
             obtained demonstrating no evidence of alcoholic or non-alcoholic steatohepatitis).&#xD;
&#xD;
          -  Patient with history of prior solid organ or allogeneic bone marrow transplant.&#xD;
&#xD;
          -  Patients with any of the following concurrent severe and/or uncontrolled medical&#xD;
             conditions which could compromise participation in the study:&#xD;
&#xD;
               1. Clinically significant cardiac diseases, including any of the following:&#xD;
&#xD;
             i. History or presence of serious uncontrolled ventricular arrhythmias&#xD;
&#xD;
        ii.Clinically significant resting bradycardia&#xD;
&#xD;
        iii.Any of the following within 3 months prior to starting study drug: myocardial&#xD;
        infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive&#xD;
        Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA),&#xD;
        Pulmonary Embolism (PE)&#xD;
&#xD;
        iv.Uncontrolled hypertension defined by a SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg, with or&#xD;
        without anti-hypertensive medication(s)&#xD;
&#xD;
        b) Cirrhosis, chronic active hepatitis or chronic persistent hepatitis&#xD;
&#xD;
        c) Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not&#xD;
        mandatory)&#xD;
&#xD;
        d) Known diagnosis of any condition (i.e. post-hematopoietic or organ transplant,&#xD;
        rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc.) that&#xD;
        requires chronic immunosuppressive therapy. Usage of non-steroidal anti-inflammatory&#xD;
        medications (NSAIDS) for the treatment of osteoarthritis and uric acid synthesis inhibitors&#xD;
        for the treatment of gout are permitted. For questions, please consult the study chair.&#xD;
&#xD;
        e) Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active&#xD;
        or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety&#xD;
        risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women of child-bearing potential, who are biologically able to conceive, and not&#xD;
             employing two forms of highly effective contraception. Highly effective contraception&#xD;
             must be used throughout the trial and up to 8 weeks after the last dose of study drug&#xD;
             (e.g. male condom with spermicidal; diaphragm with spermicide; intra-uterine device).&#xD;
             Women of child-bearing potential, defined as sexually mature women who have not&#xD;
             undergone a hysterectomy or who have not been naturally postmenopausal for at least 12&#xD;
             consecutive months (i.e., who has had menses any time in the preceding 12 consecutive&#xD;
             months), must have a negative serum pregnancy test ≤ 14 days prior to starting study&#xD;
             drug&#xD;
&#xD;
          -  Fertile males not willing to use contraception, as stated above&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noah Hahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noah Hahn, MD</last_name>
    <phone>443-287-2886</phone>
    <email>nhahn4@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanya O'neal, RN</last_name>
    <phone>410-955-9797</phone>
    <email>toneal2@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Institute of Urologic Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Bradley</last_name>
      <phone>310-794-3452</phone>
      <email>MABradley@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Karim Chamie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wacker</last_name>
      <phone>720-848-3527</phone>
      <email>michael.wacker@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly O'Connor</last_name>
      <phone>773-702-4653</phone>
      <email>koconnor@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter O'Donnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noah Hahn, MD</last_name>
      <phone>443-287-2886</phone>
      <email>nhahn4@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rana Sullivan, RN</last_name>
      <phone>410-614-6337</phone>
      <email>tomalra@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Cooper</last_name>
      <phone>212-304-6342</phone>
      <email>kb2870@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

